InModeINMD
About: InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.
Employees: 599
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
0% less call options, than puts
Call options by funds: $28.8M | Put options by funds: $28.9M
2% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 45
2.55% less ownership
Funds ownership: 54.49% [Q3] → 51.93% (-2.55%) [Q4]
3% less funds holding
Funds holding: 252 [Q3] → 245 (-7) [Q4]
6% less capital invested
Capital invested by funds: $781M [Q3] → $734M (-$47.2M) [Q4]
34% less repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 98
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Jefferies Matthew Taylor 33% 1-year accuracy 1 / 3 met price target | 4%downside $15 | Hold Maintained | 14 Apr 2025 |
Barclays Matt Miksic 40% 1-year accuracy 16 / 40 met price target | 86%upside $29 | Overweight Maintained | 5 Feb 2025 |
Financial journalist opinion
Based on 6 articles about INMD published over the past 30 days









